- Home
- NIVF vs QNRX Comparison
NIVF vs QNRX Comparison
Compare NIVF & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- QNRX
- Stock Information
- Founded
- NIVF 2011
- QNRX 2018
- Country
- NIVF Hong Kong
- QNRX United States
- Employees
- NIVF 76
- QNRX N/A
- Industry
- NIVF
- QNRX Medical/Dental Instruments
- Sector
- NIVF
- QNRX Health Care
- Exchange
- NIVF NYSE
- QNRX Nasdaq
- Market Cap
- NIVF 2.1M
- QNRX 2.5M
- IPO Year
- NIVF N/A
- QNRX N/A
- Fundamental
- Price
- NIVF $0.35
- QNRX $7.12
- Analyst Decision
- NIVF
- QNRX
- Analyst Count
- NIVF 0
- QNRX 0
- Target Price
- NIVF N/A
- QNRX N/A
- AVG Volume (30 Days)
- NIVF 6.2M
- QNRX 355.0K
- Earning Date
- NIVF 01-01-0001
- QNRX 05-08-2025
- Dividend Yield
- NIVF N/A
- QNRX N/A
- EPS Growth
- NIVF N/A
- QNRX N/A
- EPS
- NIVF N/A
- QNRX N/A
- Revenue
- NIVF $5,433,375.00
- QNRX N/A
- Revenue This Year
- NIVF N/A
- QNRX N/A
- Revenue Next Year
- NIVF N/A
- QNRX N/A
- P/E Ratio
- NIVF N/A
- QNRX N/A
- Revenue Growth
- NIVF 5.79
- QNRX N/A
- 52 Week Low
- NIVF $0.11
- QNRX $5.01
- 52 Week High
- NIVF $3.28
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- NIVF 34.92
- QNRX 46.54
- Support Level
- NIVF $0.26
- QNRX $5.27
- Resistance Level
- NIVF $0.38
- QNRX $7.22
- Average True Range (ATR)
- NIVF 0.06
- QNRX 1.12
- MACD
- NIVF 0.02
- QNRX 0.22
- Stochastic Oscillator
- NIVF 45.61
- QNRX 62.79
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.